




Lab | Central
2016 IMPACT REPORT



Dear Friends,

The results are in and there's no doubt about it: 2016 was another banner year for us. In our third year of growth, we can conclude confidently that LabCentral has truly changed the way life-science companies are built. LabCentral is proud to have established the *de-facto* standard for life-science co-working facilities worldwide. We collaborated with Harvard University in opening the Pagliuca Harvard Life Lab on the campus of Harvard Business School to offer this new model to their community. Our LabCentral companies continued their successful trajectories in 2016, raising over \$300M in additional financing, adding 402 new jobs to the economy, and building dozens of new partnerships - while developing lifesaving medicines and creating breakthroughs in medical science.

This year, we will grow LabCentral substantially as part of our on-campus expansion to more than twice our current size. The addition of the second and third floors will allow us to grow our community and help more entrepreneurs launch their startups. Please take a few minutes to look through this report and join me in thanking our sponsors, residents, and most of all, our incredible team at LabCentral.

If you have not visited recently, I invite you to sign up for a public tour, join one of our many social, community, and networking events, or come enjoy the work of the local artists featured at Gallery 1832. We look forward to seeing you!


Thank you,



Johannes Fruehauf, M.D., Ph.D.
President and Executive Director

\$1.1 BILLION

RAISED BY OUR CUTTING-EDGE COMPANIES OVER
THE LAST THREE YEARS



SINCE 2014

51
COMPANIES SERVED

24
ALUMNI COMPANIES

717
JOBS CREATED

261
PATENTS FILED

45
PATENTS GRANTED


77%
NET PROMOTER SCORE

A CLEAR IMPACT


By the end of our third full year of operation, LabCentral was home to 25 resident companies, and the proud *alma mater* of 24 companies (two of which have been acquired). Since moving out, our companies have continued to raise significant financing from leading venture capital firms, highlighting their position as players in the national biotech scene. In 2016, LabCentral resident and alumni companies raised approximately **\$331 million**, bringing the grand total of funding raised since our opening in 2014 to approximately **\$1.1 billion**.

2016 FUNDING RAISED*

By LabCentral Residents and Alumni



2016 U.S. BIOTECH SERIES A FUNDING*



\$351 MILLION

CLOSED IN SERIES A VENTURE CAPITAL SINCE 2014

*Self reported data from 86% of resident and alumni companies - this data does not include any totals for companies with successful exits

SOURCES OF COMPANY TECHNOLOGY



- Massachusetts academic institution
- Massachusetts hospital
- Self-Invented
- CRO
- Commercial License

LabCentral attracts companies with a variety of technological and business strategy profiles. Most of the intellectual property these companies are built on is rooted in academic and hospital research laboratories. While 83% of this technology is from laboratories within Massachusetts, the remaining 17% has been brought in from international or out-of-state laboratories or licensing agreements.



Our model relies heavily on involvement of industry sponsors. These sponsors are a vital part of the web we have built to connect startups to the innovation ecosystem. It is our role to facilitate the growth and strengthening of this network for our companies and sponsors.

154
COMPANY-SPONSOR
RELATIONSHIPS

IN THE NEWS

2016 was an exciting time for the LabCentral community. Resident and alumni companies achieved notable accomplishments and met critical milestones in their progress.

“ AFFINIVAX PROVES YOU CAN LAUNCH A BIOTECH WITHOUT THE HELP OF VCS ”

-Boston Business Journal, February 2016

In February 2016, **Affinivax** received a \$2.5 million investment from the Bill & Melinda Gates Foundation. This funding is being used to advance Affinivax's vaccine targeting *Streptococcus pneumoniae* toward clinical testing. Its Multiple Antigen Presentation System (MAPS) overcomes the limitations of current conjugate vaccine technology and provides broader protection against invasive disease colonization and transmission. This offers the potential to protect against all pneumococcal serotypes, a significant advancement in pneumococcal prevention. Affinivax continues to progress its research at LabCentral as a company in residence since 2014.

“ UNUM THERAPEUTICS ANNOUNCES ACTIVE INVESTIGATIONAL NEW DRUG APPLICATION... ”

-Business Wire, June 2016

In June, **Unum** announced its first active Investigational New Drug (IND) application for treatment of patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma. This trial will be the first U.S. based clinical program for Unum. The company began its research at LabCentral with a single lab bench and a team of two in 2014, and grew rapidly as it secured funding. The company built out its own facility and became a LabCentral alumna in the summer of 2015.

“ HUMAN HEARING LOSS COULD BE REVERSIBLE ”

-The Atlantic, July 2016

In 2016, LabCentral resident company, **Audion Therapeutics**, used funds from Series B and grant funding from the Horizon 2020 program in Europe for its ongoing lead program development. The company is on track toward clinical trials to treat hearing loss caused by damaged or dead sensory hair cells. Audion has called LabCentral home throughout its early research and proof-of-concept work. The facility gives this Dutch-based company a physical presence in Cambridge's epicenter of biotech research.

“ VEDANTA NABS \$50 M TO EXPAND MICROBIOME INTO IMMUNE-BOOSTING THERAPIES ”

-Xconomy, June 2016

“ POLARIS CASHES IN ITS CHIPS AS LANGER-BACKED ARSIA IS AUCTIONED OFF TO EAGLE FOR UP TO \$78 M ”

-Endpoint News, November 2016

“ THIRD ROCK VENTURES LAUNCHES FULCRUM THERAPEUTICS WITH \$55 M SERIES A INVESTMENT ”

-Business Wire, July 2016

“ AQUINNAH PHARMACEUTICALS NAMED MOST INNOVATIVE NEURODEGENERATIVE RESEARCH COMPANY IN 2016 ”


-PR Newswire, December 2016

“ YUMANITY THERAPEUTICS CLOSES \$45 M SERIES A FINANCING ”

-Business Wire, February 2016


“ ENBIOTIX TO COLLABORATE WITH MAYO CLINIC ON ENGINEERED PHAGE PROGRAM ”

-Business Wire, June 2016







AN ENGINE FOR JOB CREATION

LabCentral companies continue to add value to the local economy. Since its inception, LabCentral has created a grand total of **717 new jobs**. In 2016 alone, we saw 402 of these jobs created by resident companies who were able to focus startup resources on hiring additional scientific staff as progress warranted; and by alumni companies. Based on the 2016 Bureau of Labor's Occupational Employment Statistics, these 402 jobs added roughly \$43.7 million in annual wages to the local Massachusetts economy. LabCentral itself has added 23 jobs to the grand total of 717 jobs.




LabCentral companies draw their talent from local institutions such as Harvard University, MIT, Brigham and Women's Hospital, MGH and more.



*Leadership position defined as C-level, VP, director, and senior and principal scientist

CELEBRATING OUR COMPANIES

In 2016, LabCentral saw the next generation of life-sciences companies graduate successfully into spaces of their own. Many of these companies have remained in the Cambridge area, with 93 percent within four miles of LabCentral. These companies continue to contribute to the thriving innovation ecosystem of Kendall Square.



LABCENTRAL ALUMNI



229,140
SQ. FEET
of real estate occupied by alumni companies in Massachusetts

17.7
AVERAGE MONTHS spent at LabCentral by 2016 alumni companies

25
PATENTS granted to residents and alumni in 2016

113
NEW PATENTS filed by LabCentral companies in 2016

27
NEW LICENSING AGREEMENTS formed by our teams in 2016


A THRIVING HUB FOR INNOVATION

LabCentral hosted more than 150 events and saw 10,098 unique visitors in 2016. Programming included seminars on technical and research trends, business development, and social events such as artist receptions and ping pong tournaments. At LabCentral, fostering a sense of community that promotes openness and collaboration is an important part of how we accomplish our mission. We are excited that for the first time, over 10,000 visitors benefited from this approach and were exposed to new ideas.


150 EVENTS AND TRAININGS



- Technical/Scientific
- Industry Networking
- Community Event
- Business & Entrepreneurship
- STEM Education



PROMOTERS (9-10)



The Net Promoter Score (NPS) measures the willingness of our scientists and entrepreneurs to recommend LabCentral to others. Our NPS places us among the highest ranked brands worldwide for user satisfaction.

NEUTRAL (7-8)

DETRACTORS (<7)



ATTENTION FROM AROUND THE WORLD

LabCentral continues to serve as the new model for building early-stage biotech companies. LabCentral was honored to host **24 international groups** in 2016, as well as other notable figures including representatives from the **U.S. Department of Defense**, **France's Minister of State for Higher Education & Research**, and **ambassadors from Lithuania, Germany, Hungary** and more.

COMMUNITY ENGAGEMENT

STEM

LabCentral has hosted many STEM events over the course of the past year, including the graduation event for the BioBuilder High School Apprenticeship Challenge. This program trains high school students from Boston and Cambridge for eight weeks in advance of summer internships in life-science laboratories throughout Greater Boston. These internships were supported in part by funds from the Massachusetts Life Sciences Center.

For the third year running, LabCentral was home to YouthCITIES, allowing students to gain hands-on experience solving big medical problems through innovation and entrepreneurship. In addition, LabCentral welcomed students from regional and international schools for a glimpse of cutting-edge research in biotech from LabCentral's entrepreneurs.



GALLERY 1832

Gallery 1832 is a curated gallery at LabCentral, hosting a rotation of local artists. Built in 1832, this building has a notable history of science and innovation. It was the home of the Edwin Land and Polaroid laboratories, received the first long distance call from Alexander Graham Bell, and saw the invention of the pipe wrench and center aisle railroad car. Gallery 1832 is a tribute to this colorful history.

Gallery 1832 provides residents and visitors with new avenues to find inspiration for innovation. LabCentral considers the gallery space an important part of stimulating creative thinking and it is just one of the many ways LabCentral is continuing to build community connections.





GROWING TO MEET THE NEED

PAGLIUCA HARVARD LIFE LAB

In the fall of 2016, The Harvard Innovation Labs opened the Pagliuca Harvard Life Lab with the direction of Lab Central. This curated wet lab co-working space, built using LabCentral's design guidance and co-working philosophy, is located adjacent to the i-lab on the Allston campus of Harvard. It is designed to serve high-potential ventures founded by Harvard students, alumni, and faculty and is operated by LabCentral. Our team equips, oversees, and operates the facility on a day-to-day basis.




EXPANSION

In the summer of 2017, LabCentral is more than doubling its footprint at 700 Main Street to become home to even more early-stage life-science companies. This new space will offer additional options for growing teams with flexible laboratory and office solutions. Our expansion will also provide current and future resident companies with additional laboratory resources and technical capabilities in microbiology, mass spectrometry, and microscopy – more tools to advance breakthroughs for medical science.



A BIG THANK YOU TO OUR 2016 SPONSORS

FOUNDING



PLATINUM



GOLD



GENERAL SPONSORS





Lab | Central

700 MAIN STREET, NORTH | CAMBRIDGE, MA 02139

LABCENTRAL.ORG | 617.863.3650 |  @LABCENTRAL